DecisionDx-Melanoma Identifies Early Distant Metastases
Castle’s DecisionDx-Melanoma, a 31-gene expression profile (GEP) test, can identify patients at risk of developing early distant metastases (DM) to the central nervous system (CNS), lung, liver, and bone and can guide risk-appropriate surveillance strategies, potentially improving survival outcomes.